Exosomes as potential biomarkers and targeted therapy in colorectal cancer

A mini-review

Research output: Contribution to journalShort survey

15 Citations (Scopus)

Abstract

The number of colorectal cancer (CRC) cases have increased gradually year by year. In fact, CRC is one of the most widely diagnosed cancer in men and women today. This disease is usually diagnosed at a later stage of the development, and by then, the chance of survival has declined significantly. Even though substantial progress has been made in understanding the basic molecular mechanism of CRC, there is still a lack of understanding in using the available information for diagnosing CRC effectively. Liquid biopsies are minimally invasive and have become the epitome of a good screening source for stage-specific diagnosis, measuring drug response and severity of the disease. There are various circulating entities that can be found in biological fluids, and among them, exosomes, have been gaining considerable attention. Exosomes can be found in almost all biological fluids including serum, urine, saliva, and breast milk. Furthermore, exosomes carry valuable molecular information such as proteins and nucleic acids that directly reflects the source of the cells. Nevertheless, the inconsistent yield and isolation process and the difficulty in obtaining pure exosomes have become major obstacles that need to be addressed. The potential usage of exosomes as biomarkers have not been fully validated and explored yet. This review attempts to uncover the potential molecules that can be derived from CRC-exosomes as promising biomarkers or molecular targets for effective diagnosing of CRC.

Original languageEnglish
Article number583
Pages (from-to)583
Number of pages1
JournalFrontiers in Pharmacology
Volume8
Issue numberAUG
DOIs
Publication statusPublished - 28 Aug 2017

Fingerprint

Exosomes
Colorectal Neoplasms
Biomarkers
Therapeutics
Human Milk
Saliva
Nucleic Acids
Urine
Biopsy
Survival
Serum
Pharmaceutical Preparations
Neoplasms

Keywords

  • Biomarkers
  • Colorectal cancer
  • Exosomes
  • Molecular target
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Exosomes as potential biomarkers and targeted therapy in colorectal cancer : A mini-review. / Hon, Kha Wai; Abu, Nadiah; Ab Mutalib, Nurul Syakima; A. Jamal, A. Rahman.

In: Frontiers in Pharmacology, Vol. 8, No. AUG, 583, 28.08.2017, p. 583.

Research output: Contribution to journalShort survey

@article{b9fe539b5c4644df892a7085bf829994,
title = "Exosomes as potential biomarkers and targeted therapy in colorectal cancer: A mini-review",
abstract = "The number of colorectal cancer (CRC) cases have increased gradually year by year. In fact, CRC is one of the most widely diagnosed cancer in men and women today. This disease is usually diagnosed at a later stage of the development, and by then, the chance of survival has declined significantly. Even though substantial progress has been made in understanding the basic molecular mechanism of CRC, there is still a lack of understanding in using the available information for diagnosing CRC effectively. Liquid biopsies are minimally invasive and have become the epitome of a good screening source for stage-specific diagnosis, measuring drug response and severity of the disease. There are various circulating entities that can be found in biological fluids, and among them, exosomes, have been gaining considerable attention. Exosomes can be found in almost all biological fluids including serum, urine, saliva, and breast milk. Furthermore, exosomes carry valuable molecular information such as proteins and nucleic acids that directly reflects the source of the cells. Nevertheless, the inconsistent yield and isolation process and the difficulty in obtaining pure exosomes have become major obstacles that need to be addressed. The potential usage of exosomes as biomarkers have not been fully validated and explored yet. This review attempts to uncover the potential molecules that can be derived from CRC-exosomes as promising biomarkers or molecular targets for effective diagnosing of CRC.",
keywords = "Biomarkers, Colorectal cancer, Exosomes, Molecular target, Targeted therapy",
author = "Hon, {Kha Wai} and Nadiah Abu and {Ab Mutalib}, {Nurul Syakima} and {A. Jamal}, {A. Rahman}",
year = "2017",
month = "8",
day = "28",
doi = "10.3389/fphar.2017.00583",
language = "English",
volume = "8",
pages = "583",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Exosomes as potential biomarkers and targeted therapy in colorectal cancer

T2 - A mini-review

AU - Hon, Kha Wai

AU - Abu, Nadiah

AU - Ab Mutalib, Nurul Syakima

AU - A. Jamal, A. Rahman

PY - 2017/8/28

Y1 - 2017/8/28

N2 - The number of colorectal cancer (CRC) cases have increased gradually year by year. In fact, CRC is one of the most widely diagnosed cancer in men and women today. This disease is usually diagnosed at a later stage of the development, and by then, the chance of survival has declined significantly. Even though substantial progress has been made in understanding the basic molecular mechanism of CRC, there is still a lack of understanding in using the available information for diagnosing CRC effectively. Liquid biopsies are minimally invasive and have become the epitome of a good screening source for stage-specific diagnosis, measuring drug response and severity of the disease. There are various circulating entities that can be found in biological fluids, and among them, exosomes, have been gaining considerable attention. Exosomes can be found in almost all biological fluids including serum, urine, saliva, and breast milk. Furthermore, exosomes carry valuable molecular information such as proteins and nucleic acids that directly reflects the source of the cells. Nevertheless, the inconsistent yield and isolation process and the difficulty in obtaining pure exosomes have become major obstacles that need to be addressed. The potential usage of exosomes as biomarkers have not been fully validated and explored yet. This review attempts to uncover the potential molecules that can be derived from CRC-exosomes as promising biomarkers or molecular targets for effective diagnosing of CRC.

AB - The number of colorectal cancer (CRC) cases have increased gradually year by year. In fact, CRC is one of the most widely diagnosed cancer in men and women today. This disease is usually diagnosed at a later stage of the development, and by then, the chance of survival has declined significantly. Even though substantial progress has been made in understanding the basic molecular mechanism of CRC, there is still a lack of understanding in using the available information for diagnosing CRC effectively. Liquid biopsies are minimally invasive and have become the epitome of a good screening source for stage-specific diagnosis, measuring drug response and severity of the disease. There are various circulating entities that can be found in biological fluids, and among them, exosomes, have been gaining considerable attention. Exosomes can be found in almost all biological fluids including serum, urine, saliva, and breast milk. Furthermore, exosomes carry valuable molecular information such as proteins and nucleic acids that directly reflects the source of the cells. Nevertheless, the inconsistent yield and isolation process and the difficulty in obtaining pure exosomes have become major obstacles that need to be addressed. The potential usage of exosomes as biomarkers have not been fully validated and explored yet. This review attempts to uncover the potential molecules that can be derived from CRC-exosomes as promising biomarkers or molecular targets for effective diagnosing of CRC.

KW - Biomarkers

KW - Colorectal cancer

KW - Exosomes

KW - Molecular target

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85028530075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028530075&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00583

DO - 10.3389/fphar.2017.00583

M3 - Short survey

VL - 8

SP - 583

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - AUG

M1 - 583

ER -